Status:
COMPLETED
Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions
Lead Sponsor:
Cairo University
Conditions:
Heart Failure With Reduced Ejection Fraction
Renal Insufficiency
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Heart Failure (HF) poses a major health burden in various populations, with devastating annual rates of morbidity and mortality. It is estimated that 1%-to-2% of the general population suffer from the...
Detailed Description
Population of study \& disease condition Chronic heart Failure patients with reduced ejection fraction, (LVEF \<40%) associated with moderate impairment of renal functions, (eGFR by Cockroft-Gold equa...
Eligibility Criteria
Inclusion
- Age between 18 and 80 years
- Patients with signs and/or symptoms of heart failure NYHA II, III or IV, with echocardiographic diagnosis of HFrEF..
- Moderate impairment of renal functions, assessed by measuring serum creatinine levels then estimating the glomerular filtration rate (eGFR) by Cockroft-Gold equation to be (60-40 ml/min/m2).
Exclusion
- Refusal to participate in the study.
- Known allergy to enalapril/telmisartan components.
- Pregnant and lactating ladies.
- Severe renal impairment defined as eGFR\<30ml/min/m2 at time of enrollment to the study.
- Known cases of bilateral severe renal artery stenosis.
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT04736329
Start Date
February 1 2021
End Date
October 31 2022
Last Update
June 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasralainy hospital, faculty of medicine, Cairo university
Cairo, Egypt, 11562